Tune Therapeutics
Company type: Therapeutics
Main focus: Epigenetically-modified cell therapy
Company stage: Pre-clinical
Diseases: Various
Genome-editing tool: CRISPR-based epigenome editing
Funding stage: Series B
Location: Seattle and Durham, USA
Website: https://tunetx.com
Pipeline: Not disclosed
Partners:
Tune Therapeutics is a pre-clinical stage company focused on the development of new therapeutics based on CRISPR-Cas epigenome editors. Epigenome editing allows for fine-tuning of gene expression ( up-regulation and/or down-regulation) without the risks associated with permanent genomic edits. As of June 2023, Tune Therapeutics is advancing proof-of-concept studies showcasing its technology, the latest being stable down-regulation of the PCSK9 gene in non-human-primates.